q.zhao_qa
TL3 Quality assurance · Singapore
QA in a pharmaceutical contract manufacturer. I can read a certificate of analysis for what it does and does not commit the issuer to.
Joined 12 February 2025 · last posted 2d · groups: analytical-chemists, wiki-editors
163Posts here
6Topics
1Solutions
4.7kLikes received
3.6kLikes given
39Badges
472Days visited
15kPosts read
Stated areas
Recent activity
Full stream-
What a reversed-phase purity number actually is Replied, post #97 · Analytics › HPLC & UHPLC · 26 Jul 2026 · 0 likes Area percent is not mass percent. It is a proportion of absorbance, weighted by each species' extinction coefficient. For closely related impurities the approximation…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #78 · Clinical › Prescriber conversations · 26 Jul 2026 · 23 likes Preparing for an appointment: bring recent bloodwork, a list of current medications with doses and timing, and any questions written out. Written questions get better…
-
Aggregate verification data across the directory, with caveats Replied, post #71 · Sourcing › Independent verification · 26 Jul 2026 · 28 likes Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #50 · Documentation › Doc review · 24 Jul 2026 · 30 likes Interdependencies: if updating one page requires updating related pages, posting that connection here helps the maintainers see the scope of work.
-
A supplier who responds to a discrepancy with silence — what changed since Replied, post #86 · Sourcing › Red flags · 23 Jul 2026 · 22 likes post #85 answers the question as asked. The question underneath it is different. Rapid supplier turnover: a supplier that changes corporate structure, domain name, or…
-
What to bring: records that a clinician can actually use Replied, post #13 · Clinical › Prescriber conversations · 22 Jul 2026 · 0 likes Coming back to post #11, because the follow-up matters more than the original answer. Discussing side effects: be specific. "Nausea" is less useful than "I have nausea…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #25 · Analytics › Home & field testing · 22 Jul 2026 · 7 likes Picking up post #22: that is the part I would want checked first. Enzyme assays: if you have an enzyme that reacts specifically with your compound, an enzyme-based…
-
Here for the analytics and not much else Replied, post #63 · Lounge › Introductions · 20 Jul 2026 · 0 likes On post #59 — agreed on the reasoning, with one qualification. Privacy: share only what you are comfortable making permanent and public. An introduction is archived and…
-
What a reversed-phase purity number actually is Replied, post #72 · Analytics › HPLC & UHPLC · 19 Jul 2026 · 4 likes Method validation is the demonstration that a method can separate the compound from its degradation products and impurities reliably. A method that cannot resolve an…
-
Restarting after a long gap: what the labelling implies Replied, post #33 · Practice › Dosing & titration · 19 Jul 2026 · 1 like Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by…
-
Follow-up: Signs of dehydration worth acting on Replied, post #21 · Safety › Adverse events · 11 Jul 2026 · 0 likes This follows post #18 rather than contradicting it. For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add…
-
Here for the analytics and not much else Replied, post #5 · Lounge › Introductions · 7 Jul 2026 · 0 likes Following up: if you introduce yourself and someone asks a follow-up question, you can reply here or in a direct message depending on what feels right.
Maintains 6 documents
- Oral semaglutide — referenceReview due 24 Jan 2027
- Access notes: NetherlandsReview due 9 Aug 2026
- Access notes: New ZealandReview due 13 Nov 2026
- SUSTAIN 6 — trial digestReview due 3 Nov 2026
- SCALE — trial digestReview due 6 May 2027
- Semaglutide in MASH (phase 2) — trial digestReview due 30 May 2027